메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국병원약사회 병원약사회지 병원약사회지 제35권 제2호
발행연도
2018.1
수록면
154 - 176 (23page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

이 논문의 연구 히스토리 (2)

초록· 키워드

오류제보하기
Purpose : There is compelling evidence that the fixed-dose combination with oxycodone and naloxone (Targin PR tab􀋓) is useful for the management of baseline pain control for cancer patients. The purpose of the study was to evaluate the appropriate use of Targin PR tab􀋓 in the cancer-related pain management. Methods : The retrospective study was conducted in cancer patients who were prescribed the Targin PR tab􀋓(5/2.5 mg, 10/5 mg, 20/10 mg, 40/20 mg) from January 2016 to August 2016, and who were then reviewed using the self-developed Drug Use Evaluation (DUE) criteria. Results : 86 patients were finally enrolled in the study. The justification of use for the study was with 70 cases (81.4%). The adequacy of the initial dose and usage was noted at 54 cases (62.8%) and 79 cases (91.9%), respectively. The Targin PR tab􀋓 was prescribed to 32 patients (37.2%) who were contraindicated in the use of this drug. Notably, the drug-related adverse effects were reported in 24 cases (27.9%). It is noted that most of the side effects experienced by participants in this study were from gastrointestinal events, such as constipation. In 72 of the cases (83.7%), the Targin PR tab􀋓 was prescribed with other drugs, potentially changing its PK/PD profile. The compliance rates of the initial pain evaluation during the patient hospitalization stage were 85 cases (98.8%). However, the appropriate control of breakthrough pain and reevaluation of pain showed in 64 cases (74.4%). In 52 cases (60.5%), the dose or type of drug is effectively modified according to the appropriate pain control guidelines in the cancer patients. Conclusion : The justification of the use indicated in accordance with the medication was considered as highly suitable in this case. However, according to regular pain evaluation, the modification of the dose and the associated formulation were slightly inadequate. These results suggest the need to upgrade the management of the cancer-related-pain to help cancer patients improve their quality of life with the use of this drug therapy.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0